Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,141.60
(
0.53%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
100.65
(
2.39%
)
Bitcoin
74,793.43
(
-0.07%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Sunday, 12/09/2007 10:56:16 AM

Sunday, December 09, 2007 10:56:16 AM

Post# of 257253
Anticoagulant Index

Rivaroxaban
#msg-25147464 Rivaroxaban bests Lovenox in VTE prevention
#msg-24337258 Bayer plans 50,000(!)-patient study

Apixaban
#msg-19134406 PFE, BMY ink $1B collaboration
#msg-21044973 Apixaban non-inferior to Warfarin in phase-2

Dabigatran
#msg-25152872 BI starts phase-2 in ACS
#msg-21155926 Dabigatran non-inferior to Lovenox in VTE prevention

Arixtra
#msg-10569101 Arixtra bests Lovenox in ACS

M118
#msg-24457684 M118 has big sales potential
#msg-23604134 MNTA starts phase-2 in ACS
#msg-19617749 Start of phase-1 using sub-Q formulation
#msg-25147975 M118 vs oral FXa inhibitors

General
#msg-18759853 Overview of the new oral anticoagulants

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now